Supernus Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US8684591089

SecuritySUPN / Supernus Pharmaceuticals, Inc.
InstitutionAssetmark, Inc
Latest Disclosed Ownership43,972 shares
Latest Disclosed Value $ 2,272,913
Assetmark, Inc reports 6.23% increase in ownership of SUPN / Supernus Pharmaceuticals, Inc.

On May 6, 2026 - Assetmark, Inc filed a 13F-HR form disclosing ownership of 43,972 shares of Supernus Pharmaceuticals, Inc. (US:SUPN) valued at $2,272,913 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 23, 2026 disclosing 41,394 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of 6.23% during the quarter. The current value of the position is $1,936,307 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 43,972 2,578 6.23 2,273 10.45 0.0046
2026-01-23 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 41,394 1,670 4.20 2,057 8.38 0.0042
2025-11-06 2025-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 39,724 3,020 8.23 1,898 64.19 0.0041
2025-08-04 2025-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 36,704 -1,259 -3.32 1,157 -7.00 0.0027
2025-05-06 2025-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 37,963 4,748 14.29 1,243 3.50 0.0034
2025-02-06 2024-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 33,215 -227 -0.68 1,201 15.26 0.0033
2024-11-01 2024-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 33,442 908 2.79 1,043 19.77 0.0030
2024-08-13 2024-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 32,534 1,432 4.60 870 -17.92 0.0027
2024-05-07 2024-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 31,102 1,403 4.72 1,061 23.40 0.0034
2024-02-09 2023-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 29,699 1,121 3.92 859 9.15 0.0031
2023-10-27 2023-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 28,578 629 2.25 788 -6.31 0.0032
2023-08-11 2023-06-30 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 27,949 1,956 7.53 840 -10.73 0.0033
2023-05-05 2023-03-31 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 25,993 1,423 5.79 942 7.42 0.0039
2023-02-10 2022-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 24,570 558 2.32 876 7.75 0.0038
2022-11-01 2022-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 24,012 22,107 1,160.47 813 1,378.18 0.0038
2022-08-03 2022-06-30 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 1,905 283 17.45 55 5.77 0.0002
2022-05-13 2022-03-31 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 1,622 -15 -0.92 52 8.33 0.0002
2022-02-14 2021-12-31 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 1,637 53 3.35 48 14.29 0.0002
2021-11-12 2021-09-30 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 1,584 15 0.96 42 -12.50 0.0002
2021-08-16 2021-06-30 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 1,569 -3 -0.19 48 17.07 0.0002
2021-05-14 2021-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 1,572 81 5.43 41 7.89 0.0002
2021-02-10 2020-12-31 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 1,491 161 12.11 38 35.71 0.0002
2020-11-13 2020-09-30 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 1,330 420 46.15 28 27.27 0.0002
2020-08-11 2020-06-30 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 910 846 1,321.88 22 2,100.00 0.0002
2020-05-12 2020-03-31 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 64 -22 -25.58 1 -50.00 0.0000
2020-02-11 2019-12-31 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 86 8 10.26 2 0.00 0.0000
2019-11-13 2019-09-30 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 78 78 2 0.0000
2018-05-16 2018-03-31 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 0 -17 -100.00 0 -100.00
2018-02-13 2017-12-31 13F SUPERNUS PHARMACEUTICALS INC COM COM 868459108 17 17 1 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.